Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Unknown 1 Not yet recruiting 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 131 Breast 52 Gynecologic 38 Gastrointestinal 27 Head & Neck 26 Genitourinary 25 CNS 13 Other solid neoplasm 10 Lymphoid 10 Sarcoma 7 Dermatologic 6 Tumor-Agnostic 3 Endocrine 3 Other hematologic neoplasm 2 NET 1 Myeloid 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 13 Magnetic Resonance Spectroscopy 6 Specimen Handling 5 pembrolizumab 4 cabozantinib 4 Nivolumab 4 Octreotide 3 Lutetium-177 3 Ipilimumab 3 Everolimus 3 lenvatinib 2 avelumab 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 toripalimab 1 tislelizumab 1 telotristat ethyl 1 surufatinib 1 peposertib 1 pazopanib 1 pasireotide 1 entrectinib 1 copper dotatate CU-64 1 atezolizumab 1 abemaciclib 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Carboplatin × NET × Clear all

NCT06232564 2026-01-14

PELICAN

Imperial College London

Phase 2 Active not recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡